Presenter: Andrew Taylor, Ph.D., Services Technical Support Manager
It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate and to evaluate the potential of a drug candidate to be a victim or perpetrator. Knowing how a drug candidate is eliminated by the human body is important in understanding the potential for drug-drug interactions. Compounds with a single route of elimination have a high victim potential, which is why the FDA requires reaction phenotyping studies. This short, information-packed webinar features:
- An overview of drug metabolism studies
- 2020 FDA recommendations
- Standard CYP reaction phenotyping study designs (recombinant enzyme, chemical inhibition or correlation analysis) and when to perform them
- Test system selection and more...
Download slides: https://www.xenotech.com/webinar-slides/sekisui-xenotech_reaction-phenotyping_adme-101.pdf
Questions, comments and requests: https://www.xenotech.com/contact-us
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/scientific-resources/webinar-series
Upcoming webinar notifications: https://www.xenotech.com/newsletter-signup
Request a webinar topic: https://www.xenotech.com/scientific-resources/upcoming-webinars
About the presenter: Dr. Andrew G. Taylor received his Ph.D. from University of California San Diego. He joined SEKISUI XenoTech as a research scientist in 2017, serving as a Study Director in nonclinical drug interaction contract studies in compliance with Good Laboratory Practices (GLP), OECD Principles of GLP, &/or Japan MOHW GLP Standards and specializing in drug transport and drug metabolism studies. He became the Technical Support Manager for services in 2020 and provides valuable guidance to ensure research needs are being met.